IBRX Logbook – February 23, 2026: It Had to Be Here

1. Commercial momentum – from launch year to triple-digit growth

ANKTIVA was approved by the US FDA in April 2024 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without papillary tumors. The initial debate around IBRX was whether the company would be able to convert a complex intravesical product into real-world sales, given logistics, patient selection and payer questions. The 2025 numbers give a much clearer signal: while absolute revenue is still modest in large-cap terms, the growth slope is very steep.

Net product revenue reached $113M, a ~700% increase year-over-year, driven by both new accounts and deeper use in existing centers. Unit sales volume climbed by about +750%, which is important because it suggests that volume, not just pricing, is carrying the story. Q4 2025 revenue of $38.3M, up 431% year-over-year and 20% quarter-over-quarter, indicates that the ramp is still in progress, not plateauing.

At the same time, the company continues to invest heavily in R&D and global infrastructure. R&D expense for 2025 was $218.6M, up from $190.2M, partly due to higher manufacturing and clinical trial costs and a one-time write-off of fixed assets. SG&A decreased from $168.8M to $150.0M as litigation and consulting costs came down, but commercial and field teams are expanding to support international launches.

The cash position of $242.8M at year-end provides a buffer, but with >$200M in annual R&D plus meaningful SG&A, the cash burn remains high. The core question for the next two to three years is whether the NMIBC franchise plus the first NSCLC and lymphopenia indications can grow fast enough to reduce dependence on capital markets.

2. Global approvals – 33 countries and the first lung cancer nod

One of the standout datapoints in the new press release is the speed of ANKTIVA’s international rollout. In less than two years from the first FDA approval, the drug is now authorized in 33 countries across four major jurisdictions for BCG-unresponsive NMIBC CIS with or without papillary tumors:

• United States: FDA approval (April 2024).
• United Kingdom: MHRA authorization (July 2025).
• Kingdom of Saudi Arabia: SFDA accelerated approval (January 2026) for NMIBC and, separately, conditional accelerated approval for metastatic NSCLC in combination with checkpoint inhibitors.
• European Union: European Commission conditional marketing authorization (February 2026), covering the 27 EU member states plus Iceland, Norway and Liechtenstein.

Saudi Arabia is the first jurisdiction worldwide to approve ANKTIVA for metastatic NSCLC in combination with checkpoint inhibitors, validating the concept of ANKTIVA as a lymphocyte-stimulating backbone therapy, not just a one-off bladder cancer product. Commercial launch in KSA is planned within 60 days of the January 2026 approval, providing an early test case for NSCLC uptake.

On the ex-US front, the company plans to file for NSCLC accelerated approvals in multiple additional jurisdictions during 2026 and to engage with the US FDA on an accelerated approval pathway for NSCLC in the US. The ultimate value of ANKTIVA will depend on whether those regulatory paths translate into durable, reimbursed label expansions beyond NMIBC.

3. ANKTIVA as Cancer BioShield backbone – pipeline and 3-year plan

Beyond bladder cancer, ImmunityBio is framing ANKTIVA as a backbone cytokine for a broader Cancer BioShield platform, combining IL-15 receptor agonism with checkpoint inhibitors, CAR-NK cells and other agents across multiple tumor types and settings.

4. What really changed vs the previous IBRX “logbook”

Compared with earlier stages of the IBRX story, when the main focus was US NMIBC launch and speculation on future label expansions, this new release adds three tangible layers:

At the same time, key risks remain unchanged: high cash burn, dependence on regulatory success in NSCLC and other indications, manufacturing/CMC execution, and competition in both bladder cancer and lung cancer from established immuno-oncology players. This logbook entry does not resolve those uncertainties – it simply records that the company has moved from “idea + first approval” to “scaling product + visible global plan”.

5. Key risks and watchpoints for the next 12–24 months

As always with biotech, the upside narrative must be balanced against the practical risk factors that could derail or delay it. A non-exhaustive list of items to watch:

• Regulatory risk in NSCLC and beyond: SFDA’s NSCLC approval is an important milestone, but ex-US filings and US FDA discussions on NSCLC accelerated approval are still ahead. Any negative feedback or requirement for large, lengthy randomized trials could push timelines out.
• Execution across many trials: the Cancer BioShield plan involves numerous studies (BCG-naïve NMIBC, NSCLC 1L/2L, GI tumors, lymphoma, lymphopenia, etc.). Operational missteps, recruitment delays or inconsistent data could dilute the perceived value of the platform.
• Cash burn and financing: even with $242.8M in cash and a growing revenue base, ImmunityBio is still burning hundreds of millions per year. Unless growth accelerates dramatically, some form of financing (equity, debt or partnerships) is likely over a multiyear horizon, which can be dilutive.
• Manufacturing and supply: scaling ANKTIVA plus complex combinations (CAR-NK, M-ceNK) requires reliable CMC and supply-chain capacity. Any disruption could hit both revenue and regulators’ confidence.
• Competition: in both bladder and lung cancer, checkpoint-based combinations and new immunotherapies are a crowded, rapidly evolving field. Maintaining differentiation on efficacy, safety and cost will be crucial.

For the logbook, the takeaway is that the upside is now more visible than in the very early days – but so is the scale of execution needed to capture it. Price action will likely remain highly volatile around trial readouts and regulatory milestones.

6. Sentiment & trading notes (retail-heavy name)

As of late February 2026, IBRX trades like a classic battleground between high short interest and an extremely active retail base. After the European conditional approval and the latest ANKTIVA updates, the stock has logged moves in the 30–40% range in single sessions and is up sharply year-to-date, with frequent gap-ups and equally sharp intraday reversals.

Recent estimates place short interest in the mid-30% to mid-40% of free float, positioning IBRX among the most shorted names within its market-cap bracket. Lists that circulate on Reddit often show the ticker near the top of “most shorted” rankings, and several threads explicitly describe IBRX as a primary short-squeeze candidate after the early-2026 run, with millions of shares sold short despite the rally. At the same time, days-to-cover remain manageable thanks to very high trading volumes, which means the squeeze narrative is more about positioning and crowding than about a textbook illiquidity trap.

On Stocktwits and similar real-time chat streams, sentiment has swung violently around key headlines. In the days around the European decision and the Saudi approvals, internal sentiment gauges for IBRX moved from clearly bearish to clearly bullish / extremely bullish, with message volumes multiple times the usual baseline and a heavy focus on potential short squeeze scenarios, upside price targets and comparisons with past big winners. Around the February 18–23 window, a large portion of posts frame ANKTIVA as a multi-billion platform and talk about “multi-bagger” potential, while others focus almost entirely on options flow, call volumes and gap levels.

Reddit threads tend to be more mixed. Alongside users who embrace the squeeze narrative and see current volatility as “just the beginning”, there are detailed posts warning about the combination of very high short interest and a still-fragile balance sheet, highlighting past dilution, the scale of the clinical program and the need for further funding if the ramp in revenue and approvals does not translate into quicker self-funding. Some contributors also stress that, even after the European and Saudi moves, most of the value still depends on successful execution of the broader Cancer BioShield plan and on future randomized data.

On X/Twitter, discussion is fast and noisy: a mix of chart screenshots, talk about gaps and resistance levels, and comments on unusual options activity (very high call volume, low put-call ratios on busy days). Many messages reference the stock as a potential “short squeeze play” first and as a complex immuno-oncology story only second. For a run-up perspective, the conclusion is straightforward: the combination of crowded short interest, dense retail chatter and binary/regulatory catalysts can amplify both pre-catalyst moves and post-event drawdowns. Volatility cuts both ways and should be expected, not seen as an anomaly.